SEC 13F Intelligence

Managers / Q3 2022 · view latest →

HighVista Strategies LLC

CIK 0001335325 · 200 CLARENDON STREET, 50TH FLOOR, BOSTON, MA, 02116 · 617-406-6500

Reported Value
$175M
Q3 2022
Positions
113
Filings on Record
30
2019–present window
Filed
Nov 14, 2022
original filing

Summary

Highvista Strategies LLC reported $175M in U.S.-listed holdings across 113 positions for Q3 2022.

Its largest position, DELL, represents 6.9% of the portfolio.

Compared with Q2 2022, the fund opened 19 new positions and exited 16.

Portfolio Metrics

Turnover
+17.2%
vs prior filed quarter
Top-10 Concentration
+36.6%
share of reported value
Largest Position
+6.9%
Dell Technologies
New / Exited
19 / 16
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $116MQ4 ’18Q1 ’19: $123MQ2 ’19: $195MQ3 ’19: $147MQ4 ’19: $132MQ4 ’19Q1 ’20: $108MQ2 ’20: $121MQ3 ’20: $137MQ4 ’20: $157MQ4 ’20Q1 ’21: $135MQ2 ’21: $141MQ3 ’21: $151MQ4 ’21: $126MQ4 ’21Q1 ’22: $157MQ2 ’22: $166MQ3 ’22: $175MQ4 ’22: $168MQ4 ’22Q1 ’23: $123MQ2 ’23: $219MQ3 ’23: $216MQ4 ’23: $276MQ4 ’23Q1 ’24: $280MQ2 ’24: $274MQ3 ’24: $290MQ4 ’24: $269MQ4 ’24Q1 ’25: $260MQ2 ’25: $272MQ3 ’25: $408MQ4 ’25: $388MQ4 ’25Q1 ’26: $362Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 84.0%Other: 10.0%ADR: 3.6%ETP: 2.4%
  • Common Stock · 84.0% · $147M
  • Other · 10.0% · $18M
  • ADR · 3.6% · $6M
  • ETP · 2.4% · $4M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2022 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
NIELSEN HLDGS PLCNEW+114.2K114.2K+$3M$3M
BKIEURBLACK KNIGHT INCNEW+42.2K42.2K+$3M$3M
VMWEURVMWARE INCNEW+23.6K23.6K+$3M$3M
COGTCOGENT BIOSCIENCES INCNEW+118.9K118.9K+$2M$2M
CGEMCULLINAN ONCOLOGY INCNEW+79.9K79.9K+$1M$1M
SNDXSYNDAX PHARMACEUTICALS INCNEW+37.1K37.1K+$892,000$892,000
IMCRIMMUNOCORE HLDGS PLCNEW+16.6K16.6K+$779,000$779,000
SGENUSDSEAGEN INCNEW+5.7K5.7K+$777,000$777,000

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2022

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1DELLDELL TECHNOLOGIES INChistory →CL C6.94%$12M355.4K
2MAMASTERCARD INCORPORATEDhistory →CL A6.01%$11M37.0K
3FISVFISERV INChistory →COM4.61%$8M86.3K
4VVISA INChistory →COM CL A4.39%$8M43.3K
5MSD ACQUISITION CORPUNIT 03/25/20262.83%$5M500.0K
6PYPLPAYPAL HLDGS INChistory →COM2.62%$5M53.3K
7CHNGUSDCHANGE HEALTHCARE INChistory →COM2.55%$4M162.1K
8CPNGCOUPANG INChistory →CL A2.44%$4M256.3K
9RLAYRELAY THERAPEUTICS INChistory →COM2.14%$4M167.4K
10RPTXREPARE THERAPEUTICS INChistory →COM2.11%$4M304.2K
11APLSUSDAPELLIS PHARMACEUTICALS INChistory →COM2.09%$4M53.5K
12CYTKCYTOKINETICS INChistory →COM NEW2.02%$4M73.2K
13ACRSACLARIS THERAPEUTICS INChistory →COM1.96%$3M217.8K
14CTXSEURCITRIX SYS INChistory →COM1.86%$3M31.4K
15ISHARES TRRUS 1000 VAL ETF1.85%$3M23.8K
16BCYCBICYCLE THERAPEUTICS PLChistory →SPONSORED ADS1.82%$3M136.8K
17NIELSEN HLDGS PLCSHS EUR1.81%$3M114.2K
18FT2FIRST HORIZON CORPORATIONhistory →COM1.77%$3M135.4K
19TGNATEGNA INChistory →COM1.70%$3M144.0K
20ATVIEURACTIVISION BLIZZARD INChistory →COM1.70%$3M40.0K
21TWTRUSDTWITTER INChistory →COM1.60%$3M64.0K
22BKIEURBLACK KNIGHT INChistory →COM1.56%$3M42.2K
23TVTXTRAVERE THERAPEUTICS INChistory →COM1.56%$3M110.7K
24KURAKURA ONCOLOGY INChistory →COM1.55%$3M198.1K
25VMWEURVMWARE INChistory →CL A COM1.44%$3M23.6K
26FATEFATE THERAPEUTICS INChistory →COM1.43%$3M111.5K
27NOVOCURE LTDORD SHS1.22%$2M28.0K
28VRDNVIRIDIAN THERAPEUTICS INChistory →COM1.20%$2M102.4K
29CATALYST PARTNRS ACQUISITN CUNIT 99/99/99991.13%$2M200.0K
30RCUSARCUS BIOSCIENCES INChistory →COM1.07%$2M71.7K
31CRNXCRINETICS PHARMACEUTICALS INhistory →COM1.03%$2M92.0K
32COGTCOGENT BIOSCIENCES INChistory →COM1.01%$2M118.9K
33CHINOOK THERAPEUTICS INCCOM0.94%$2M83.6K
34BMEABIOMEA FUSION INCCOM0.81%$1M144.7K
35CYMABAY THERAPEUTICS INCCOM0.79%$1M395.3K
36GENERATION BIO COCOM0.76%$1M249.0K
37DYNDYNE THERAPEUTICS INCCOM0.74%$1M102.4K
38GOSSGOSSAMER BIO INCCOM0.66%$1M96.8K
39RLMDRELMADA THERAPEUTICS INCCOM0.64%$1M30.1K
40CGEMCULLINAN ONCOLOGY INCCOM0.59%$1M79.9K
41EWTXEDGEWISE THERAPEUTICS INCCOM0.58%$1M103.5K
42DBCINVESCO DB COMMDY INDX TRCKUNIT0.58%$1M42.4K
43ASCENDIS PHARMA A/SSPONSORED ADR0.58%$1M9.8K
44ANABANAPTYSBIO INCCOM0.54%$944,00037.0K
45MSFTMICROSOFT CORPCOM0.53%$929,0004.0K
46SNDXSYNDAX PHARMACEUTICALS INCCOM0.51%$892,00037.1K
47NBIXNEUROCRINE BIOSCIENCES INCCOM0.51%$889,0008.4K
48SRPTSAREPTA THERAPEUTICS INCCOM0.51%$885,0008.0K
49ACADACADIA PHARMACEUTICALS INCCOM0.50%$872,00053.3K
50ALNYALNYLAM PHARMACEUTICALS INCCOM0.48%$848,0004.2K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$362M156May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$388M145Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$408M148Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$272M146Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$260M148May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$269M137Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$290M142Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$274M138Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$280M131May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$276M126Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$216M132Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$219M134Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$123M108May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$168M105Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$175M113Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$166M110Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$157M86May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$126M69Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$151M127Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$141M116Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$135M125May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$157M117Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$137M113Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$121M100Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$108M65May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$132M119Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$147M126Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$195M108Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$123M112May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$116M113Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.